Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.86B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.91M
Average 1.84M
IMVT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Immunovant, Inc.NASDAQ: IMVT
Cash & Equivalents · Q2 FY2027 · quarter ended Sep 2026
Cash & equivalents rises 38.4% from a year ago
Cash & equivalents stood at $722.27M at the end of Q2 FY2027, up 38.4% from a year earlier and down 9.5% from the prior quarter. Over 3 fiscal years it compounded at +33.8% a year.
Context
- Cash & equivalents amounted to 94.9% of total assets at the end of Q2 FY2027, up 5.4 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +38.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2026
- 902.11M USD
- Year-over-year change
- +26.4%
- 4-year CAGR
- +16.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 902.11M | +26.4% |
| FY2025 | 2025-03-31 | 713.97M | +12.4% |
| FY2024 | 2024-03-31 | 635.37M | +68.7% |
| FY2023 | 2023-03-31 | 376.53M | -23.8% |
| FY2022 | 2022-03-31 | 493.82M | — |
Cash & Equivalents vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's Sep 2026 cash & equivalents of $722.27M is the highest of the 11 companies compared; the peer median is $180.92M.
- Its year-over-year change of +38.4% is the 6th highest of 10, against a peer median of +80.4%.
- Cash & equivalents amounts to 94.9% of total assets for IMVT, versus a peer median of 71.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $722.27M | +38.4% | +33.8% | 94.9% | |
| Mar 2026 | $500.22M | +154.5% | +18.1% | 66.9% | |
| Sep 2026 | $429.38M | +479.6% | -8.2% | 27.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $248.47M | — | — | 85.5% |
| Mar 2026 | $248.47M | +151.9% | +49.5% | 75.4% | |
| Mar 2026 | $186.63M | +1204.7% | -47.5% | 98.4% | |
| Mar 2026 | $175.21M | +80.4% | +5.0% | 66.6% | |
| Mar 2026 | $116.64M | -11.5% | +0.6% | 78.7% | |
| Mar 2026 | $75.08M | -2.1% | -17.3% | 18.6% | |
| Mar 2026 | $50.75M | -22.5% | +3.2% | 79.7% | |
| Mar 2026 | $28.66M | -5.6% | -23.9% | 14.4% | |
| Peer median (excluding IMVT) | $180.92M | +80.4% | +0.6% | 71.1% | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 493.82M | 376.53M | 635.37M | 713.97M | 902.11M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 12.86M | 885K | 5.5M | 2.51M | 3.95M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 24.9M | 51.18M | 42.76M |
| Total Current Assets | 512.93M | 404.33M | 665.77M | 767.66M | 948.82M |
| Property, Plant & Equipment (Net) | 2.63M | 1.51M | 595K | 942K | 515K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 347K | 0 | 553K |
| Other Non-current Assets | 0 | 0 | 0 | 7.62M | 7.68M |
| Total Non-current Assets | 2.63M | 1.51M | 942K | 8.56M | 8.75M |
| Total Assets | 515.56M | 405.84M | 666.71M | 776.22M | 957.57M |
| Account Payables | 18.63M | 1.35M | 7.16M | 17.66M | 7.54M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 171K | 350K | 14.74M | 15.62M | 16.77M |
| Total Current Liabilities | 44.52M | 43.3M | 48.61M | 68.78M | 104.42M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 347K | 0 | 553K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 1.22M | 47K | 347K | 0 | 553K |
| Total Liabilities | 45.74M | 43.34M | 48.96M | 68.78M | 104.98M |
| Common Stock | 12K | 13K | 14K | 16K | 20K |
| Retained Earnings | (355.39M) | (566.35M) | (825.68M) | (1.24B) | (1.75B) |
| Accumulated OCI | 404K | 852K | 1.91M | 1.46M | 730K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 469.83M | 362.49M | 617.76M | 707.45M | 852.59M |
| Total Debt | 2.36M | 1.22M | 138K | 98K | 72K |
| Net Debt | (491.45M) | (375.31M) | (635.23M) | (713.87M) | (902.04M) |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.